Question explored with the scientific record
Conversation so far
Answered on this page ↓
what is CBT-1
The short version: CBT-I is cognitive behavioral therapy for insomnia, a structured sleep-retraining program, not a drug. It is the best-evidenced option for chronic insomnia, and the honest gain is modest.
CBT-I teaches you to rebuild the bed-sleep link. It combines stimulus control (get out of bed when awake), sleep restriction (compress time in bed to match actual sleep), and cognitive work on the anxious thoughts that keep you wired [5]. The core problem it targets is hyperarousal, a body stuck in a low-grade alert state at night [6].
The evidence is real. A 2015 Annals of Internal Medicine review found CBT-I cut time to fall asleep by about 19 minutes and time awake after sleep onset by about 26 minutes, and raised sleep efficiency by about 10 points [2]. A network meta-analysis of 52 studies and 12,544 people found every delivery format beat waitlist, with live sessions showing larger effects than self-help [3]. In cancer patients, nurse-delivered CBT-I improved sleep efficiency by about 10 points and cut wake time by 38 minutes, though the 6-month advantage over usual care faded [1].
| Outcome | Change with CBT-I |
|---|---|
| Time to fall asleep | about 19 min less [2] |
| Time awake after sleep onset | about 26 min less [2] |
| Sleep efficiency | about 10 points higher [2] |
| Total sleep time | about 7.6 min more, not always significant [2] |
The mechanism is not fully nailed down. A systematic review of sleep restriction therapy found poor-quality studies and no clear proof of how it works [4]. The behavioral package works; the precise lever is still being argued.
My call: CBT-I is worth trying first for chronic insomnia, with realistic expectations of 20 to 30 minutes of improvement, not a cure. Confidence: moderate.
Sources used 6
-
Randomized Controlled Clinical Effectiveness Trial of Cognitive Behavior Therapy Compared With Treatment As Usual for Persistent Insomnia in Patients With Cancer
A pragmatic, two-center randomized controlled trial demonstrates that nurse-delivered cognitive-behavioral therapy for persistent insomnia in cancer patients improves sleep efficiency and reduces sleep onset latency and wake after sleep onset, with associated gains in quality of…
DOI: 10.1200/jco.2007.13.9006 -
Cognitive Behavioral Therapy for Chronic Insomnia
CBT-i significantly improves diary-based sleep onset latency, wake after sleep onset, and sleep efficiency in adults with chronic insomnia, with benefits maintained after treatment and minimal adverse effects.
DOI: 10.7326/M14-2841 -
Comparative efficacy of onsite, digital, and other settings for cognitive behavioral therapy for insomnia: a systematic review and network meta-analysis
This study conducts a comprehensive frequentist network meta-analysis of cognitive-behavioral therapy for insomnia (CBT-I) across onsite, digital, and other delivery settings, finding all CBT-I settings improve insomnia severity versus waitlist with no clear superior setting, th…
DOI: 10.1038/s41598-023-28853-0 -
How does sleep restriction therapy for insomnia work? A systematic review of mechanistic evidence and the introduction of the Triple-R model
A systematic review of mechanistic evidence for sleep restriction therapy (SRT) in adults with insomnia, concluding limited high-quality support for proposed mechanisms and introducing the Triple-R model (Restricting, Regularising, Reconditioning) to guide future mechanistic res…
DOI: 10.1016/j.smrv.2018.07.005 -
Understanding and Treating Insomnia
Insomnia is prevalent and comorbid across the lifespan; CBT-I and its behavioral/cognitive components are efficacious and durable for primary and comorbid insomnia, though access and mechanistic evidence remain limited.
DOI: 10.1146/annurev.clinpsy.3.022806.091516 -
The Nature of Insomnia
A clinical information supplement that reviews the nature, diagnostic criteria, prevalence, risk factors, comorbidities, and pathophysiology of insomnia, emphasizing hyperarousal as a core mechanism, and outlining behavioral and pharmacologic treatment options.
DOI: 10.1017/s1092852900026109